Bone Oncology

Selected publications

• The Bone Marrow Microenvironment in Multiple Myeloma Conference (2010)
• Host-derived MMP-7 decreases myeloma progression in vivo: An unexpected role for MMP-7 and osteopontin in myeloma pathogenesis Conference (2011)
• Increasing adiponectin via an apolipoprotein peptide mimetic, L-4F, increases bone formation in normal mice and prevents myeloma bone disease in vivo Conference (2011)
• Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease Blood 118 (2011)
• Tumor-host cell interactions in the bone disease of myeloma Bone 48 (2011)
• Bone marrow stromal cells create a permissive microenvironment for myeloma development: A new stromal role for Wnt inhibitor Dkk1 Cancer Res 72 (2012)
• Decreased bone marrow-derived adiponectin contributes to myeloma pathogenesis in vivo Conference (2010)
• A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease Biol Direct 5 (2010)
• Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo Am J Hematol 84 (2009)
• A murine model of myeloma that allows genetic manipulation of the host microenvironment Dis Model Mech 2 (2009)
• EphB4 Expression in Osteoblasts is Regulated by Myeloma Cells and the Wnt Signaling Pathway. Conference (2008)
• Increasing wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo Blood 111 (2008)
• Osteoclasts in Myeloma Are Derived from Gr-1(+)CD11b(+) Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo Blood 112 (2008)
• Wnt signaling: Bone's defense against myeloma Blood 112 (2008)
• Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment Leukemia 21 (2007)
• Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells Plos One 7 (2012)
• BTK inhibition in myeloma: Targeting the seed and the soil Blood 120 (2012)
• The pathogenesis of the bone disease of multiple myeloma Bone 42 (2008)
• Sulforaphane - A new therapy for mutliple myeloma? Calcified Tissue International 83 (2008)
• Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts. Conference (2008)
• Host Bone Marrow-Derived Stromal Cells Promote Myeloma Initiation and Development of Osteolysis Conference (2008)
• Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis Conference (2007)
• Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase J Pharmacol Exp Ther 322 (2007)
• The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo Conference (2007)
• Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche Conference (2007)
• Myeloma cells decrease EphB4 expression in osteoblasts; A novel mechanism for regulation of bone formation in multiple myeloma Conference (2007)
• Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma Conference (2007)
• Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease Conference (2007)
• Apomine™, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo Int J Cancer 120 (2007)
• The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells Conference (2006)
• Novel insights into the anti-tumour mechanism of action of apomine and its synergistic interaction with lovastatin in myeloma cells in vitro Conference (2006)
• Lithium inhibits the development of myeloma bone disease in vivo. Conference (2006)
• Histone deacetylase 1 (HDAC1) regulates dickkopf 1 (DKK1) expression: Implications for myeloma bone disease. Conference (2006)
• The importance of the bone marrow microenvironment in multiple myeloma; Differential responses to lithium in vivo Conference (2006)
• Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells Int J Cancer 119 (2006)
• Apomine, an inhibitor of HMG-COA-reductase, does not act by inhibiting protein prenylation in human myeloma cells in vitro Conference (2005)
• Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors. Conference (2005)
• Advances in the management of myeloma bone disease Expert Opin Pharmacother 6 (2005)
• NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro Conference (2004)
• Risedronate, and its phosphonocarboxylate analogue NE10790, both induce apoptosis, but have differential effects on the cell cycle and protein prenylation in human myeloma cells. Conference (2004)
• Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival J Bone Miner Res 18 (2003)
• Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease Cancer 97 (2003)
• Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 (2003)
• Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss? Bone 30 (2002)
• Zoledronic acid prevents the development of myeloma bone disease and increases survival Journal of Bone and Mineral Research 17 (2002)
• Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro. Conference (2002)
• APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo. Conference (2002)
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Bone 28 (2001)
• Bisphosphonates and in vivo models of multiple myeloma - Reply British Journal of Haematology 113 (2001)
• Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma Blood 98 (2001)
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Blood 98 (2001)
• Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand. Journal of Bone and Mineral Research 15 (2000)
• The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma Br J Haematol 111 (2000)
• Bisphosphonates: Mechanisms of action in multiple myeloma Acta Oncol 39 (2000)
• Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 96 (2000)
• Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma. Blood 96 (2000)
• Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation. British Journal of Haematology 105 (1999)
• Anti-tumour activity of bisphosphonates in human myeloma cells Leukemia and Lymphoma 32 (1998)
• The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 58 (1998)
• Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity Br J Haematol 98 (1997)